AstraZeneca
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Local Phase 4 Pan-European SMART Study
- Conditions
- Asthma
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2010-03-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8424
- Registration Number
- NCT00463866
- Locations
- 🇬🇧
Research Site, Yaxley, United Kingdom
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT00463814
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
- Conditions
- HypercholesterolemiaDyslipidemia
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 760
- Registration Number
- NCT00463606
- Locations
- 🇺🇸
Site Reference ID/Investigator# 4387, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 5585, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 4483, Gilbert, Arizona, United States
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
- Conditions
- Lymphoma
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00460460
- Locations
- 🇺🇸
Research site, Buffalo, New York, United States
🇨🇦Research Site, Toronto, Ontario, Canada
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
- Conditions
- Psychotic DisordersSchizophreniaSchizoaffective Disorders
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 234
- Registration Number
- NCT00457899
- Locations
- 🇬🇧
Research Site, Warrington, United Kingdom
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00454805
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
AZD8330 First Time in Man in Patients With Advanced Malignancies
- Conditions
- Cancer
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 83
- Registration Number
- NCT00454090
- Locations
- 🇳🇴
Research Site, Oslo, Norway
Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis
- Conditions
- Psychosis
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00449397
- Locations
- 🇦🇺
Research Sites, Melbourne, Australia
A Two-week Study Assessing the Onset of Effect Questionnaire (OEQ) Administered Daily Versus Weekly in Adult Subjects
- Conditions
- Asthma
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 123
- Registration Number
- NCT00449527
- Locations
- 🇺🇸
Research Site, Tacoma, Washington, United States
A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
- Conditions
- Asthma
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 134
- Registration Number
- NCT00449501
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States